Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) EPS (Basic): 2021-2025

Historic EPS (Basic) for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Sep 2025 value amounting to -$0.37.

  • Amylyx Pharmaceuticals' EPS (Basic) rose 65.42% to -$0.37 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.79, marking a year-over-year increase of 53.14%. This contributed to the annual value of -$4.43 for FY2024, which is 706.85% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported EPS (Basic) of -$0.37 as of Q3 2025, which was up 19.57% from -$0.46 recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' EPS (Basic) ranged from a high of $0.33 in Q2 2023 and a low of -$4.15 during Q4 2021.
  • In the last 3 years, Amylyx Pharmaceuticals' EPS (Basic) had a median value of -$0.42 in 2025 and averaged -$0.45.
  • Its EPS (Basic) has fluctuated over the past 5 years, first spiked by 135.48% in 2023, then plummeted by 8,850.00% in 2024.
  • Quarterly analysis of 5 years shows Amylyx Pharmaceuticals' EPS (Basic) stood at -$4.15 in 2021, then soared by 85.06% to -$0.62 in 2022, then skyrocketed by 111.29% to $0.07 in 2023, then crashed by 871.43% to -$0.54 in 2024, then skyrocketed by 65.42% to -$0.37 in 2025.
  • Its EPS (Basic) stands at -$0.37 for Q3 2025, versus -$0.46 for Q2 2025 and -$0.42 for Q1 2025.